NCT01675895

Brief Summary

The main objective was to test the hypothesis that adding lidocaine to hyperbaric levobupivacaine could change the duration of levobupivacaine spinal block.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jul 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2009

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

August 24, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 30, 2012

Completed
Last Updated

December 18, 2012

Status Verified

December 1, 2012

Enrollment Period

2 years

First QC Date

August 24, 2012

Last Update Submit

December 17, 2012

Conditions

Keywords

Hyperbaric LevobupivacaineİntrathecalLidocaineTUR-P

Outcome Measures

Primary Outcomes (1)

  • The duration of the spinal block (S1 regression of the block)

    the time between the intrathecal injection and sensorial block regression to S1 dermatome, measured in minutes

    participanta will be followed on the operation day

Secondary Outcomes (1)

  • postoperative care unit stay

    participants will be followed on the operation day

Other Outcomes (1)

  • maximum block level

    participants will be followed on the operation day

Study Arms (2)

Group Levobupivacaine lidocaine

EXPERIMENTAL

Group Levobupivacaine lidocaine Spinal anesthesia with 1.5 ml hyperbaric levobupivacaine (6.75 mg) + 0.3 ml 2 % lidocaine

Drug: Levobupivacaine lidocaine spinal anesthesia

Group Control

ACTIVE COMPARATOR

Group Control levobupivacaine spinal anesthesia with levobupivacaine (6.75 mg) + saline

Drug: levobupivacaine Spinal anesthesia

Interventions

Spinal anesthesia

Also known as: Chirocaine, Lidocaine
Group Levobupivacaine lidocaine

spinal anesthesia

Also known as: Chirocaine
Group Control

Eligibility Criteria

Age40 Years - 80 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • elective transurethral resection of the prostate (TUR-P)

You may not qualify if:

  • patients with contraindications for spinal anesthesia,
  • known sensitivity to the study drugs,
  • emergency cases, and
  • patients who refused spinal anaesthesia were excluded

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara Diskapi Yildirim Beyazit Teaching and Research Hospital

Ankara, 06110, Turkey (Türkiye)

Location

Related Publications (1)

  • Lee SJ, Bai SJ, Lee JS, Kim WO, Shin YS, Lee KY. The duration of intrathecal bupivacaine mixed with lidocaine. Anesth Analg. 2008 Sep;107(3):824-7. doi: 10.1213/ane.0b013e3181806149.

    PMID: 18713891BACKGROUND

MeSH Terms

Conditions

Prostatic Hyperplasia

Interventions

LevobupivacaineLidocaine

Condition Hierarchy (Ancestors)

Prostatic DiseasesGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

BupivacaineAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesAcetanilides

Study Officials

  • Taylan Akkaya, MD

    Ankara Diskapi Yildirim Beyazit Teaching and Research Hospital, Turkey.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 24, 2012

First Posted

August 30, 2012

Study Start

July 1, 2009

Primary Completion

July 1, 2011

Study Completion

July 1, 2011

Last Updated

December 18, 2012

Record last verified: 2012-12

Locations